2 recruiting, 1 active not recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Kerry Rogers: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 30 | 2024-11-07 | 2026-02-19 |
| Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Ibrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Loss of Chromosome 17p | Phase 2 | Withdrawn | Kerry Rogers | 2020-03-11 | 2021-11-05 | |
| Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia Bcl-2 Inhibitor GDC-0199, Obinutuzumab, Ibrutinib - Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kerry Rogers | 87 | 2015-08-03 | 2026-06-15 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Chromosome 17 deletion (1)
venetoclax (4) · Biopsy (2) · Specimen Handling (2) · ibrutinib (2) · Magnetic Resonance Spectroscopy (1) · obinutuzumab (1) · pirtobrutinib (1) · zanubrutinib (1)
United States (3)